Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Year range
1.
Biomolecules & Therapeutics ; : 331-341, 2021.
Article in English | WPRIM | ID: wpr-889613

ABSTRACT

Liver cancer is a common tumor and currently the second leading cause of cancer-related mortality globally. Liver cancer is highly related to inflammation as more than 90% of liver cancer arises in the context of hepatic inflammation, such as hepatitis B virus and hepatitis C virus infection. Despite significant improvements in the therapeutic modalities for liver cancer, patient prognosis is not satisfactory due to the limited efficacy of current drug therapies in anti-metastatic activity. Therefore, developing new effective anti-cancer agents with anti-metastatic activity is important for the treatment of liver cancer. In this study, SP-8356, a verbenone derivative with anti-inflammatory activity, was investigated for its effect on the growth and migration of liver cancer cells. Our findings demonstrated that SP-8356 inhibits the proliferation of liver cancer cells by inducing apoptosis and suppressing the mobility and invasion ability of liver cancer cells. Functional studies revealed that SP-8356 inhibits the mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways, which are related to cell proliferation and metastasis, resulting in the downregulation of metastasis-related genes. Moreover, using an orthotopic liver cancer model, tumor growth was significantly decreased following treatment with SP-8356. Thus, this study suggests that SP-8356 may be a potential agent for the treatment of liver cancer with multimodal regulation.

2.
Biomolecules & Therapeutics ; : 331-341, 2021.
Article in English | WPRIM | ID: wpr-897317

ABSTRACT

Liver cancer is a common tumor and currently the second leading cause of cancer-related mortality globally. Liver cancer is highly related to inflammation as more than 90% of liver cancer arises in the context of hepatic inflammation, such as hepatitis B virus and hepatitis C virus infection. Despite significant improvements in the therapeutic modalities for liver cancer, patient prognosis is not satisfactory due to the limited efficacy of current drug therapies in anti-metastatic activity. Therefore, developing new effective anti-cancer agents with anti-metastatic activity is important for the treatment of liver cancer. In this study, SP-8356, a verbenone derivative with anti-inflammatory activity, was investigated for its effect on the growth and migration of liver cancer cells. Our findings demonstrated that SP-8356 inhibits the proliferation of liver cancer cells by inducing apoptosis and suppressing the mobility and invasion ability of liver cancer cells. Functional studies revealed that SP-8356 inhibits the mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways, which are related to cell proliferation and metastasis, resulting in the downregulation of metastasis-related genes. Moreover, using an orthotopic liver cancer model, tumor growth was significantly decreased following treatment with SP-8356. Thus, this study suggests that SP-8356 may be a potential agent for the treatment of liver cancer with multimodal regulation.

3.
Journal of Medical Research ; : 71-76, 2008.
Article in Vietnamese | WPRIM | ID: wpr-686

ABSTRACT

Introduction: Diabetes is a serious metabolic disease with chronic and acute complications, especially atherosclerosis. The increase of blood homocystein level is obviously related to blood injuries\u2019 in a number of diseases including diabetes. In Vietnam, blood Homocystein in Diabetics has not been comprehensively studied. \r\n', u'Objectives: The study was conducted with two surveyed groups. Determination of blood homocystein concentration in type 2 diabetics in comparison with a group of normal people. \r\n', u'Subjects and method: The study was conducted on a sample of 57 type 2 diabetics according to WHO-2001 standards and a group of 46 normal people. Concentration of blood homocystein was assayed by a competition fluorescence immunoassay, and by other experiments according to normal biochemical methods.\r\n', u'Results: The tHcy concentration in diabetics is 12.19 \xb1 3.47 mmo/L and in the normal group is 7.87 \xb1 2.26 IJmo/L. \r\n', u'Conclusion: The tHcy concentration in the 57 type 2 diabetics group has a statistically increasing mean in comparison with the normal group for both men and women. However, there is no comparative difference in the tHcy concentration of diabetics in gender and age categories. \r\n', u'

SELECTION OF CITATIONS
SEARCH DETAIL